Residual DNA Size Analysis Kit-Human cell

As the biopharmaceutical field grows, the need for strict quality control and safety measures has become critical, especially in the production of biologics such as monoclonal antibodies, vaccines, and gene therapies. A key aspect of this quality control is the monitoring and analysis of residual host cell DNA (rcDNA) in biologics derived from human cells. The presence of rcDNA raises regulatory and safety issues, requiring the development and improvement of analytical techniques to ensure compliance with strict industry standards.

Regulatory agencies such as the FDA have clear and strict limits on the amount and length of residual DNA in the final product, stipulating that no more than 10 ng per dose in a biologic. In addition to quantity, the size of the residual DNA fragments is also very important. Smaller DNA fragments are generally considered to pose less safety risk than larger DNA fragments because they have a lower probability of encoding complete genes that may cause adverse biological effects. The Human Cell Residual DNA Size Analysis Kit was developed to meet the precise need to detect and quantify the size distribution of residual DNA fragments in biopharmaceutical products. The kit uses advanced molecular biology techniques to provide accurate and reproducible results and is an important tool for manufacturers to ensure product safety and regulatory compliance.